<DOC>
	<DOCNO>NCT02773290</DOCNO>
	<brief_summary>The objective study evaluate efficacy romiplostim administer weekly Aplastic Anemia ( AA ) patient thrombocytopenia refractory ineligible immunosuppressive therapy Japan Korea . Safety pharmacokinetics romiplostim repeat administration also assess .</brief_summary>
	<brief_title>Study Romiplostim ( AMG531 ) Subjects With Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Diagnosis Aplastic Anemia ( AA ) confirm peripheral blood bonemarrow examination , etc . Refractory least one course immunosuppressive therapy include horse rabbit antihuman thymocyte immunoglobulin ( ATG ) ; ineligible ATG treatment refractory cyclosporin ( CyA ) Thrombocytopenia define platelet count ≤ 30 × 10^9/L Preserving main organ function result screen follow ; Total bilirubin : &lt; 1.5 time upper limit laboratory normal range Alanine aminotransferase : &lt; 3.0 time upper limit laboratory normal range Aspartate aminotransferase : &lt; 3.0 time upper limit laboratory normal range Creatinine value : ≤ 2.0 mg/dL An Eastern Cooperative Oncology Group performance status score 0 2 screen ≥ 20 year age time obtain informed consent Patients provide write informed consent free participate study Concurrent active infection adequately respond appropriate therapy Bone marrow reticulin grade ≥ 2 base grade scale reticulin indicate Bone Marrow Pathology ( 2nd edition ) Proportion blast bone marrow &gt; 2 % Previous concurrent active malignancy , localize tumor diagnose one year previously treat surgically curative intent ( basal cell carcinoma ; surgically resect situ carcinoma cervix apparent success ≥ 12 month prior enrollment ; well cancer treat remain diseasefree least 5 year enrollment eligible ) Clinically significant cardiac disease ( class III IV New York Heart Association classification ; unstable angina pectoris ; myocardial infarction within 6 month enrollment ; cardiac disease accompany angioplasty stenting within 6 month enrollment ; clinically significant cardiac arrhythmia ) uncontrollable hypertension Arterial venous thrombosis within one year enrollment Positive antihuman immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C virusRNA screen Thrombocytopenia due cause ( e.g. , myelodysplastic syndrome , idiopathic thrombocytopenic purpura , liver cirrhosis ) Patients acute myeloblastic leukemia chronic myelomonocytic leukemia Concurrent occurrence hemolytic predominant paroxysmal nocturnal hemoglobinuria ( Hemolytic predominant define lactate dehydrogenase &gt; 1.5 time upper limit laboratory normal range ) Uncontrolled diabetes mellitus Receiving investigational product within 16 week romiplostim treatment initiation Receiving agent treat AA , include follow agent romiplostim treatment initiation ; ATG treatment within 6 month romiplostim treatment initiation CyA anabolic steroid treatment within 6 week romiplostim treatment initiation : However , patient treat CyA anabolic steroid least 6 month romiplostim treatment initiation may enrol blood cell count stable screening , dosage administration keep 6 week romiplostim treatment initiation romiplostim dose period . A history polyethylene glycolconjugated recombinant human megakaryocyte growth development factor , recombinant human thrombopoietin ( TPO ) , romiplostim , TPOreceptor agonists Having plan undergo hematopoietic stem cell transplantation within 1 year Having hypersensitivity recombinant protein E. coli derivative protein Lactating pregnant woman woman childbearing potential intention use oral contraceptive birth control Having abnormalities cytogenetic test bone marrow cell Patients consider ineligible study investigator subinvestigator reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aplastic Anemia</keyword>
</DOC>